Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.

Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%

Vertex Pharmaceuticals (NASDAQ:VRTX) shares surged more than 13% to a record higher Wednesday after the company announced an agreement to license CRISPR-Cas9 gene-editing technology from Editas Medicines,  In exchange for $100 million plus potential licensing fees, Vertex got non-exclusive licensing rights to medicines targeting the BCL11A gene in Sickle Cell Disease. That includes Casgevy, which was approved by the FDA earlier this month.

Vertias's $100M deal to license Editas IP sets a precedent for gene-editing therapy developers in the US

Beam Therapeutics

Intellia Therapeutics

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

3 Biotechs With Promising Gene Therapies in the Spotlight

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Editas Medicine's cash runway into 2026 CAMBRIDGE, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement.

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

Editas Medicine, Inc. (NASDAQ:EDIT ) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update December 11, 2023 1:00 PM ET Company Participants Cristi Barnett - Corporate Communications & IR Gilmore O'Neill - CEO Baisong Mei - CMO Caren Deardorf - Chief Commercial & Strategy Officer Conference Call Participants Jack Allen - Baird Gena Wang - Barclays Joon Lee - Truist Securities Samantha Semenkow - Citigroup Yanan Zhu - Wells Fargo Luca Issi - RBC Capital Markets Phil Nadeau - TD Cowen Dae Gon Ha - Stifel Eric Schmidt - Cantor Fitzgerald Brian Cheng - J.P. Morgan Jay Olson - Oppenheimer Jingming Chen - Evercore ISI Cristi Barnett Good morning, everyone, and thank you for joining the EDIT-301 Clinical Update Webinar.

Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update (Transcript)

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

Editas Medicine is developing a promising gene-editing therapy. The biotech has several data readouts planned for the next 12 months.

1 Promising Stock Down 66% That Could Skyrocket in 2024

ARK Genomic Revolution Multi-Sector ETF

Caribou Biosciences

CRISPR Therapeutics

Robinhood

Eli Lilly

Prime Medicine Inc

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

Enovix Corporation

The stock market is full of surprises that can be lucrative for investors, especially for those who can recognize early on the potential that can bring returns that are multiple times larger than the initial investment.

Hidden Gems: 2 undiscovered stocks set to soar in 2024

bluebird bio

Structure Therapeutics Inc

Some of the hottest opportunities can be found in biotech stocks. Look at gene editing companies, like CRISPR Therapeutics (NASDAQ: CRSP ), for example.

If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names

Editas Medicine, Inc. (NASDAQ:EDIT ) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - Head, Corporate Communications & IR Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Thanks for joining us today for a fireside chat with Editas. My name is Liisa Bayko.

Editas Medicine, Inc. (EDIT) 6th Annual Evercore ISI HealthCONx Conference (Transcript)

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for its simplicity and versatility. Major publicly traded CRISPR companies include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Caribou Biosciences, and Prime Medicine.

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

Advanced Micro Devices

Marathon Digital Holdings

On Nov. 25, 2022, I mentioned three stocks to buy that could soar in 2023. At the time, those included Advanced Micro Devices (NASDAQ: AMD ), which ran from $73 to $121.53; Apple (NASDAQ: AAPL ), which ran from $146 to $191.45; and Nvidia (NASDAQ: NVDA ), which ran from $152 to $504.

Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year

Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics (NASDAQ: CRSP ), a move that could set off a firestorm of interest in all things gene editing.

The 3 Best Gene Editing Stocks on the Frontier of Medicine

Opera Ltd - ADR

Analysts up and down Wall Street have high expectations for Opera Limited and Editas Medicine. Opera Limited started paying a dividend this year, even though its performance metrics are rising like a growth stock.

2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street

NVIDIA

Block

Many investors are experiencing the impact of high inflation and high interest rates for the first time. It's a time when following the daily market news can drive you crazy.

3 Long-Term Growth Stocks Analysts Are Bullish On

Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2023 Healthcare Conference November 14, 2023 1:50 PM ET Company Participants Erick Lucera - EVP, CFO Cristi Barnett - VP, Corporate Communications and IR Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha Okay, let's go ahead and get started with the next session. Thanks everyone for joining us.

Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript)

The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.

3 Biotech Stocks That Are Betting on the Future of Gene Editing

Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.

Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus

Editas Medicine, Inc. (EDIT) Q3 2023 Earnings Call Transcript

Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.81 per share a year ago.

Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored webinar

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children's to present EDIT-301 clinical data at ASH on Monday, December 11 CAMBRIDGE, Mass.

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Amgen

The Food and Drug Administration will hold an advisory committee meeting for the first CRISPR/Cas9 gene-edited product candidate this week. If approved, CRISPR Therapeutics and Vertex Pharmaceuticals' sickle cell disease therapy could generate blockbuster sales figures.

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, November 3, 2023, at 8:00 a.m. ET to discuss results for the third quarter 2023 and to provide a corporate update.

News for Editas Medicine Stock (EDIT)